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Abstract
Background: Chronic rhinosinusitis (CRS) is increasingly viewed as an inflammatory condition of
the sinonasal mucosa interacting with bacteria and/or fungi. However, factors conferring
susceptibility to disease remain unknown. Advances in genomics offer powerful tools to explore
this disorder. The goal of this study was to evaluate the effect of single nucleotide polymorphisms
(SNP) on CRS in a panel of genes related to cysteinyl leukotriene metabolism.
Methods: Severe cases of CRS and postal code match controls were recruited prospectively. A
total of 206 cases and 200 controls were available for the present study. Using a candidate gene
approach, five genes related to cysteinyl leukotriene metabolism were assessed. For each gene, we
selected the maximally informative set of common SNPs (tagSNPs) using the European-derived
(CEU) HapMap dataset. These SNPs are in arachidonate 5-lipoxygenase (ALOX5), arachidonate 5-
lipoxygenase-activating protein (ALOX5AP), leukotriene C4 synthase (LTC4S), cysteinyl
leukotriene receptor 1 (CYSLTR1) and cysteinyl leukotriene receptor 2 (CYSLTR2) genes.
Results: A total of 59 SNPs were genotyped to capture the common genetic variations within
these genes. Three SNPs located within the ALOX5, CYSLTR1 and ALOX5AP genes reached the
nominal p-value threshold (p < 0.05) for association with CRS. However, none of these SNPs resist
multiple testing adjustment.
Conclusion: While these initial results do not support that polymorphsims in genes assessed
involved in the leukotriene pathways are contributing to the pathogenesis of CRS, this initial study
was not powered to detect polymorphisms with relative risk of 2.0 or less, where we could expect
many gene effects for complex diseases to occur. Thus, despite this lack of significant association
noted in this study, we believe that validation with external populations and the use of better-
powered studies in the future may allow more conclusive findings.
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Background
Chronic rhinosinusitis (CRS) is a frequent and important
chronic disease, which causes significant patient discom-
fort and morbidity. Patients with CRS report a signifi-
cantly lower quality of life index in measures of bodily
pain and social functioning than do patients with conges-
tive heart failure, angina, chronic obstructive pulmonary
disease, and back pain [1]. In health surveys, CRS affect
more than 10% of individuals in western countries, with
an overall direct cost of CRS in the United States annually
estimated at $4.3 billion [2,3].
Despite the frequency of CRS and the costs associated
with its care, there is limited knowledge about the initial
development of disease. Our current conception of CRS is
as of a chronic inflammation of the paranasal sinus mem-
brane, which is colonised with nasal and exogenous bac-
teria that may contribute to the disorder. Histologically,
CRS is characterized by an accumulation of inflammatory
cells that are mainly eosinophils, with a neutrophilic infil-
trate only during acute infections. Numerous pro-inflam-
matory cytokines and chemokines, both Th-1 and Th-2
profiles, are over expressed in CRS. These include IL-2, IL-
4, IL-5, IL-6, IL8, IL-13 and IL-16 [4].
Current knowledge of the disease is limited to that gar-
nered by study of biopsy samples obtained from patients
affected with well-established disease, with little informa-
tion available on early events or environmental factors
associated with development of disease. Genetic studies
may thus offer a better insight into the pathogenesis of the
disorder. Recently, the primary interest in genetics has
changed from simple Mendelian diseases, for which gen-
otypes of some gene are the cause of disease, to more com-
plex diseases, for which genotypes of some set of genes
together with environmental factors merely alter the prob-
ability that an individual gets the disease, although indi-
vidual factors are typically insufficient to cause the disease
outright [5].
Reports of familial clustering of CRS support a genetic
basis for the disease [6-8]. The high prevalence of patients
with CRS in well-defined genetic disorders such as cystic
fibrosis (CF) and primary cilia dyskinesia (Kartagener's
syndrome) also supports the concept that mutated genes
play a role in the pathogenesis of the disease [9]. How-
ever, it is suspected that CRS generally encountered in
clinical practice is due to a complex interaction of multi-
ple genes rather than the single gene anomalies as
observed in CF and Kartagener's syndrome. A polygenic
model for nasal polyps was recently confirmed by segrega-
tion analysis [10]. The same study also confirms that nasal
polyp is a highly heritable disease with heritability coeffi-
cients above 60%. Interestingly, the quantitative contribu-
tion of genetic factors seems to be higher in young and
recurrent patients [6,10]. A number of genetic association
studies have been conducted to elucidate the genetic loci
conferring risk of CRS with or without nasal polyposis.
Significant difference in allele frequencies between
patients and controls were observed for polymorphisms
located in the HLA [11-14], CFTR [15], LTA [16], TGFB1
[17], IL1RN [18], and ADRB2 [19]. However, all these
findings remain to be confirmed in larger populations.
It is possible that cysteinyl leukotrienes (cysLTs) may play
a disease-regulating role in rhinosinusitis. CysLTs,
described primarily as lipid mediators involved in patho-
genesis of airway inflammation and related symptoms
such as bronchoconstriction, mucus secretion, and airway
hyperresponsiveness, are recognized now as important
mediators of cell trafficking and innate immune responses
[20]. CysLTs are synthesized through the lipoxygenase
(LO) pathway of arachidonic acid metabolism. The LO
pathway for synthesizing cysLTs has several steps, and dis-
tinct enzymes are involved in each steps, namely ara-
chidonate 5-lipoxygenase (ALOX5), arachidonate 5-
lipoxygenase-activating protein (ALOX5AP or FLAP), and
leukotriene C4 synthase (LTC4S) [21]. Effects at the cellu-
lar level are mediated via two G-protein coupled receptors
termed cysteinyl leukotriene receptor 1 (CYSLTR1) and
cysteinyl leukotriene receptor 2 (CYSLTR2) (Figure 1).
In this initial study, we propose to study the genes regulat-
ing the leukotriene pathway to identify potential poly-
morphisms involved in disease susceptibility. We hope
that identification of genetic polymorphisms involved
will lead to improved comprehension of disease patho-
genesis, and may eventually lead to more effective treat-
ment, screening, and prevention of CRS.
Methods
Population
210 individuals with severe CRS were prospectively
recruited from three tertiary rhinology clinics from July
2005 to February 2006. Four were not included in the
final analysis, as phenotypic questionnaires were incom-
plete, leaving 206 subjects for analysis. These were com-
pared to 200 control subjects. The study was approved by
the McGill University Health Centre ethics committee,
and written informed consent was obtained from all par-
ticipants.
Subjects with sever CRS were recruited from ongoing clin-
ical activities, according to pre-established clinical criteria.
Severe CRS was defined as 1) individuals with persistent
signs and symptoms of CRS with one previous endoscopic
sinus surgery for diagnosis of either chronic rhinosinusitis
with or without sinonasal polyposis or recurrent acute
sinusitis or 2) individuals with more than one surgery for
these diagnoses, regardless of outcome.BMC Medical Genetics 2008, 9:21 http://www.biomedcentral.com/1471-2350/9/21
Page 3 of 9
(page number not for citation purposes)
A standardized questionnaire assessing age, sex, ethnic
origin, and family history was obtained. Other associated
factors include smoking, presence of self-reported sea-
sonal and perennial allergies, physician diagnosed asthma
and acetylsalicylic acid intolerance were also obtained.
Information on disease related factors including age at
diagnosis, age at first surgery, number of previous surger-
ies, medications and current symptoms were determined.
Initial diagnoses were obtained from patients records, and
classified according to 2004 American Academy of
Otolaryngology-Head and Neck Surgery (AAO-HNS)
guidelines [22]. Diagnosis of aspirin sensitivity was based
on a medical history reporting symptoms including
asthma exacerbation, rhinorrhea, and nasal congestion,
after the ingestion of aspirin or other nonsteroidal anti-
inflammatory drugs. Four tubes of blood were drawn
from patients with severe CRS. Two were for DNA extrac-
tion and the others were for the measurements of serum
eosinophilia and total IgE. Blood samples were stored at -
20 degrees Celsius for 2 days then at -80 degrees Celsius
prior to use.
The control population was recruited from either patient's
spouse or non-blood relatives living in the same house-
hold or by random telephone screening matched to
affected subject's postal code. For the 30 spouse or non-
blood relative controls, whole blood was used. In the 170
control subjects recruited by telephone screening, the
Oragene kit (DNA Genotek, Ottawa, Ontario) for saliva
collection was sent to the control subject with prepaid
return postage. Saliva samples were stored at room tem-
perature as recommended by the manufacturer.
IgE and eosinophilia measurements
Blood samples for total serum IgE and eosinophilia were
processed by the hospital laboratory according to stand-
ard methods. Eosinophilia was reported as percent of total
circulating white blood cells. IgE was reported in IU, with
the upper range of normal reported as 120 IU/ml.
DNA extraction
DNA was isolated from peripheral blood leukocytes, col-
lected in citrate-treated tubes, using the Puregene DNA
isolation kit, (Gentra System, QIAGEN) following the
High Throughput Protocol for 10 ml Whole Blood pro-
vided with this kit. DNA extracted from saliva was per-
formed using the Oragene DNA Purification Protocol
(DNA Genotek, Ottawa, Ontario). Isolated DNA from
both blood and saliva was stored at -20 degrees Celsius
prior to use.
SNP selection and genotyping
SNPs were selected to capture as much information as
possible about genetic variation for each gene. That was
achieved using the European-derived (CEU) genotype
data from the International HapMap project [23] covering
ten kilobases up- and downstream of each gene. From this
dataset, a maximally informative set of SNPs were selected
for each gene using an aggressive tagging algorithm [24]
implemented in Haploview version 3.2 [25]. Minor allele
frequency and r2 thresholds were set at 0.05 and 0.8,
respectively. SNPs selected for each gene are shown in
Table 1.
SNPs were genotyped using Sequenom matrix-assisted
laser desorption/ionization time-of-flight (MALDI-TOF)
mass array spectrometer (Sequenom, San Diego, CA).
Primers were designed using the Sequenom SNP Assay
Design software version 3.0 for iPLEX reactions. A total of
59 assays were designed within a 29-, 24- and 7-plexs reac-
tions. The protocol and reaction conditions were in
accordance with the manufacturer [26].
Statistical analysis
Sample size was designed to provide 95% power to detect
common alleles (> 10%) conferring a > 3.0 -fold increase
in risk, and 50% power to detect alleles >25% that
increase risk by a factor of 2.0.
Hardy-Weinberg equilibrium (HWE) was estimated using
a χ2 test. HWE tests were performed only in females for
SNPs located on the X chromosome (SNPs located in the
Arachidonic acid metabolism Figure 1
Arachidonic acid metabolism. Candidate genes selected for 
genotyping are indicated along the cysteinyl leukotriene met-
abolic pathway. LO, lipoxygenase pathway; COX, cyclo-oxy-
genase pathway; ALOX5, arachidonate 5-lipoxygenase; 
ALOX5AP, arachidonate 5-lipoxygenase-activating protein; 
LTC4S, leukotriene C4 synthase; CYSLTR1, cysteinyl leukot-
riene receptor 1; CYSLTR2, cysteinyl leukotriene receptor 2. 
Cysteinyl leukotriene metabolites are leukotriene B4 (LTB4), 
leukotriene C4 (LTC4), leukotriene D4 (LTD4), and leukot-
riene E4 (LTE4).BMC Medical Genetics 2008, 9:21 http://www.biomedcentral.com/1471-2350/9/21
Page 4 of 9
(page number not for citation purposes)
Table 1: Association between single nucleotide polymorphisms in leukotriene pathway candidate genes and chronic rhinosinusitis.
Gene (chr) SNPs MAF Minor allele HWE p value Case, Control Ratios** p value
ALOX5AP (13) rs12430915 0.08 C 0.200 38:378, 26:346 0.271
rs4769870 0.16 T 0.080 353:61, 269:61 0.170
rs4076128 0.30 C 0.439 290:124, 255:111 0.909
rs11616333 0.05 G 0.558 22:396, 19:353 0.922
rs4769055 0.33 A 0.187 143:275, 120:252 0.561
rs9578196 0.10 T 0.408 380:38, 326:42 0.283
rs4293222 0.37 C 0.930 161:257, 134:236 0.505
rs12429692 0.26 T 1.000 118:300, 88:284 0.144
rs10162089 0.49 T 0.828 217:197, 184:186 0.453
rs4254165 0.28 C 0.928 302:114, 264:108 0.612
rs4356336 0.42 C 1.000 242:176, 208:154 0.902
rs17612127 0.08 T 0.847 40:376, 21:343 0.046
rs9506352 0.34 T 0.300 278:138, 242:128 0.674
rs9579648 0.15 C 0.317 68:350, 52:320 0.371
rs9579649 0.07 T 0.330 28:388, 24:348 0.875
rs9315051 0.08 C 1.000 33:385, 26:346 0.629
rs4420371 0.25 C 0.842 107:311, 93:277 0.882
rs4466940 0.20 T 0.295 85:329, 60:256 0.604
rs9578200 0.17 T 0.014 352:66, 307:65 0.525
rs9285076 0.22 T 0.133 326:92, 289:83 0.919
rs9670198 0.04 A 0.168 401:15, 329:13 0.887
rs4319601 0.41 T 0.064 241:163, 209:143 0.938
rs4769063 0.13 T 1.000 365:51, 322:50 0.621
rs4238139 0.28 C 0.028 117:301, 99:265 0.805
ALOX5 (10) rs3824612 0.38 T 0.263 273:145, 220:152 0.074
rs3780894 0.17 C 0.789 85:333, 52:320 0.019
rs7099684 0.19 A 0.456 82:332, 65:301 0.466
rs7919239 0.23 A 0.392 101:313, 79:293 0.293
rs2115819 0.47 C 0.414 195:219, 152:180 0.720
rs11239523 0.16 C 0.831 71:345, 55:317 0.383
rs4948672 0.46 C 0.512 203:215, 161:211 0.137
rs12264801 0.45 T 0.028 230:188, 202:168 0.904
rs3780901 0.33 C 0.440 143:271, 116:250 0.400
rs2279435 0.43 C 0.707 187:231, 156:216 0.428
rs1565096 0.23 C 0.094 323:95, 283:89 0.691
rs1487562 0.21 T 0.381 97:321, 69:301 0.117
rs2291427 0.30 T 0.870 298:120, 257:115 0.498
rs7393696 0.38 A 0.394 256:154, 207:135 0.591
rs7089063 0.24 A 0.478 112:304, 61:233 0.059
CYSLTR2 (13) rs2406939 0.36 C 0.948 152:266, 130:242 0.678
rs11617224 0.11 C 1.000 375:43, 329:41 0.719
rs6420296 0.08 C 1.000 389:29, 337:33 0.303
rs7335898 0.06 G 0.790 28:390, 18:336 0.345
rs9285169 0.09 T 0.136 43:373, 26:334 0.129
rs9595961 0.48 C 0.994 203:215, 175:195 0.722
rs17072059 0.04 T 0.784 407:11, 353:17 0.137
rs7330127 0.44 A 1.000 189:229, 155:207 0.501
rs2407249 0.21 C 0.129 88:330, 74:298 0.687
rs9568087 0.29 A 0.315 299:117, 254:108 0.600
rs12184704 0.07 C 0.057 33:385, 21:339 0.259
CYSLTR1 (X)* rs321090 0.23 C 0.605 247:60, 207:81 0.014
rs321007 0.30 C 0.916 224:84, 192:96 0.107
rs321006 0.13 T 0.423 42:266, 37:252 0.764
LTC4S (5) rs730012 0.29 C 0.403 126:292, 103:269 0.448
rs2291418 0.04 T 0.316 399:15, 347:19 0.284
rs166624 0.17 A 1.000 77:341, 56:316 0.207
HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency.
*Hardy-Weinberg and association tests were specifically calculated for the X chromosome using the method implemented in Haploview 3.32.
**Number of allele A observed in cases : number of allele B observed in cases, number of allele A observed in controls : number of allele B 
observed in controls.BMC Medical Genetics 2008, 9:21 http://www.biomedcentral.com/1471-2350/9/21
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CYSLTR1 gene). Case-control comparisons were analyzed
using a χ2 test implemented in Haploview version 3.2
[25]. A nominal p-value less than 0.0012 was considered
significant. This threshold was computed by permutation
testing to ensure a project-wide type 1 error rate of 0.05.
Results
210 patients with severe CRS were recruited. Four were
not included in the analysis, as phenotypic questionnaires
were incomplete. Table 2 shows the characteristics of cases
and controls. For cases, initial diagnosis was recurrent rhi-
nosinusitis in 12.1%, CRS without polyposis in 13.1%,
and CRS with polyposis in 74.8%. Average number of pre-
vious surgeries was 3.15 (range 1 – 20; median 2.0), with
an average age at first surgery of 38.3 years (range 1 – 76;
median 38). Medication use in this group was high, with
73.4% of patients requiring medication beyond an
inhaled nasal corticosteroid for disease control and 23.3%
remaining uncontrolled despite medication. Atopy was
present in 65.5% and asthma requiring treatment in
53.9%. Active smoking was present in 11.2%. Patients
reported blood relatives affected with CRS in 37.7% of
instances.
Measured serum biomarkers showed mean circulating
eosinophilia of 4.4% (range 0 – 25%; median 4.0%) with
33.5% of patients demonstrating > 5% eosinophilia.
Mean total serum IgE was 155.9 IU (range 2 – 1460,
median = 85.0) with 41.1% having levels IgE > 120 IU/ml.
Genetic analysis
The assay conversion rate was 95% (56 out of 59) and the
average genotyping success rate for the 56 SNPs yielding
working assays was 98.7%. The remaining 3 SNPs
(rs4503649, rs12561364 and rs1359112) failed the geno-
typing assay and were discarded from the analyses. All
SNPs were in HWE, except rs9578200 where the p-value
was 0.014 (Table 1).
A final collection of 56 SNPs was tested for association.
Figure 2 illustrates the location of each SNPs relative to
the intron-exon structure of each gene. Figure 2 also
depicts the genetic association results between SNPs and
CRS. Three SNPs were found to be associated with CRS at
a p value < 0.05. These SNPs were found in the ALOX5
(rs3780894), ALOX5AP (rs17612127) and CYSTLR1
(rs321090) genes. However, none of these SNPs reached
the multiple testing p value threshold of 0.0012. The link-
age disequilibrium pattern for each gene in our popula-
tion is illustrated in Figure 3.
Spurious associations cause by population stratification is
always a concern in genetic case-control association stud-
ies. Accordingly, the analyses were repeated with only
White individuals (162 controls and 173 cases). Globally
the results were very similar. All SNPs were in HWE and
the minor allele frequencies were practically unchanged
compared to all ethnicities included. The SNPs ALOX5-
rs3780894 and CYSLTR1-rs321090 remained statistically
significant (p = 0.037 and 0.031, respectively). In contrast,
SNP ALOX5AP-rs17612127 was no longer significant (p =
0.144).
Discussion
In this study, we have analyzed SNPs covering 5 genes
implicated in the cysLT pathway in a case-control series of
patients with severe CRS. After adjustment of multiple
testing, there were no significant associations observed
between severe CRS and genetic variants within these
genes. Rather than suggest that there is no role for poly-
morphisms in the leukotriene cascade, it suggests that the
effect of polymorphisms in cysLTs is less than the power
detectable by our population size, which is well-powered
to detect only polymorphisms in common alleles which
confer a relative risk (RR) of 3.0 or greater, and only mod-
erately powered to detect polymorphisms with a RR of
2.0. In this study, the minor allele of the most significant
polymorphisms conferred a RR of 1.45 (ALOX5-
rs3780894), 1.67 (ALOX5AP-rs17612127) and 0.69
(CYSLTR1-rs321090). Most genes for complex diseases
that have been described have an effect in this range or
less.
Although SNP CYSLTR1-rs321090 is not significant after
multiple testing correction, the results observed in the cur-
rent study replicated the previous association reported by
Hao et al [27]. In fact, the polymorphism, labeled 927T/C
(rs320995) was significantly associated with atopy sever-
ity in a group of asthmatic families. Interestingly, this pol-
ymorphism is in tight linkage disequilibrium (LD) with
rs321090 (r2 = 0.82 based on the CEU genotyping dataset
of the International HapMap project [23]). In both stud-
ies, the common allele is more frequent in cases than con-
trols. In contrast, the current study does not corroborate
Table 2: Characteristics of the subjects
Cases Controls
n2 0 6 2 0 0
Age (years) 52.3 ± 13.0 48.8 ± 15.0
Male: Female ratio 1.10 0.79
Ethnic group (%)
White 85.2 89.5
Middle East 4.9 4.4
Jewish 5.4 1.1
Asian 1.5 1.1
First Nation 1.5 0.6
Black 1.0 0.6
Hispanic 0.5 1.1
Pacific Islander 0.0 1.7
Values are means ± SD for age.BMC Medical Genetics 2008, 9:21 http://www.biomedcentral.com/1471-2350/9/21
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the previous association between SNP LTC4S-rs730012
(also known as -444A/C) and allergic rhinitis [28]. How-
ever, a number of controversies exist concerning the role
of this polymorphism in allergic-related diseases [29,30].
Accordingly, larger and well-powered studies will be
required to determine the role of this polymorphism in
pathogenesis of these diseases.
Beside the lack of power, other factors may explain the
absence of significant results. First, we have studied what
is a relatively heterogeneous population, with several dif-
ferent initial diagnoses, some unresponsive to therapy
effective in others and different levels of serum biomark-
ers of inflammation. It is possible that the effect of cysLTs
may be different within these groups and less noticeable
in the group as a whole. Analysis of subgroups within our
population may be of benefit but will be limited by sam-
ple size. Secondly, the control group utilized must also be
considered. The group used has been selected for compa-
rability in terms of environment rather than for absence of
the disease. With the prevalence of self-reported chronic
sinusitis being reported as high a 16% and the incidence
of allergies being over 20%, confusion with these other
disorders may make it hard to differentiate from these
other disorders.
Leukotrienes have nevertheless been implicated in CRS in
other models and several studies have shown that leukot-
rienes may be involved in the development of the disor-
der. CysLT metabolites, leukotriene C4 (LTC4),
leukotriene D4 (LTD4), and leukotriene E4 (LTE4) likely
contribute to the pathogenesis of chronic rhinosinusitis
through their effects on microvascular leakage, epithelial
cell activation, elevated mucus secretion, and mucosal
inflammation [31]. CysLTs also appear to be related to the
severity of eosinophilic inflammation [32].
CysLTs appear related to nasal polyposis. In an examina-
tion of 27 patients by Kaplan et al. [33] patients with sino-
nasal polyps were noted by radioimmunoassay to have
Genetic association of SNPs in the leukotriene pathway genes with chronic rhinosinusitis Figure 2
Genetic association of SNPs in the leukotriene pathway genes with chronic rhinosinusitis. Each subfigure presents the result of 
one gene. The top line indicates the gene name and symbol. The upper part of each subfigure shows the exon-intron structure 
of the gene and the localization of the genotyped SNPs. The coding exons are shown in black and the untranslated regions are 
shown in grey. The lower part of each subfigure illustrated the association results for chronic rhinosinusitis. The x-axis shows 
the localization of the gene and SNPs on build 36. The y-axis shows the p values on a log scale. The lower and upper dash lines 
represent p value thresholds of 0.05 and 0.0012, respectively. The gene structure for CYSLTR2 was taken from Fukai et al. 
[38]. The upper and lower parts of each subfigure are shown on the same scale.BMC Medical Genetics 2008, 9:21 http://www.biomedcentral.com/1471-2350/9/21
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Linkage disequilibrium (LD) plots surrounding genes involved in the leukotriene pathway Figure 3
Linkage disequilibrium (LD) plots surrounding genes involved in the leukotriene pathway. The LD plots were generated by 
Haploview 3.32. [25]. Gene symbols are indicated at the top of each graph. The upper part of each graph illustrated the Hap-
Map info track including the location of the gene on build 34. The white horizontal bar below the info track illustrated the loca-
tion of SNPs on a physical scale. The color of squares illustrate the strength of pairwise r2 values on a black and white scale 
where black indicates perfect LD (r2 = 1.00) and white indicates perfect equilibrium (r2 = 0). The r2 LD value is also indicated 
within each square. Blocks are defined using the Gabriel et al. [39] definition. Failed and monomorphic SNPs as well as SNPs 
not in Hardy-Weinberg equilibrium are not illustrated.
ALOX5  CYSLTR2 
LTC4S  ALOX5AP
CYSLTR1 BMC Medical Genetics 2008, 9:21 http://www.biomedcentral.com/1471-2350/9/21
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elevated levels of LTC4. Patients with sinonasal polyposis
with recurrences within 18 months of surgery had higher
levels of LTC4 when compared with those patients that
did not have recurrences. In another study of 58 individu-
als, Steinke et al. [34] reported that chronic hyperplastic
eosinophilic sinusitis is characterized by the increased
presence of CysLTs when compared with concentrations
seen in tissue from patients with chronic inflammatory
sinusitis or healthy sinus tissue. Specifically implicating
the polyp tissue as the source of these cysLTs, Higashi et
al. [35] found that there were significant decreases in the
urinary LTE4 concentrations before and after the sinus
surgery for patients with chronic hyperplastic rhinosinusi-
tis with nasal polyposis. In support of this, a recent study
showed that urinary LTE4 concentration is highly signifi-
cant in 10 patients with aspirin-intolerant asthma (AIA)
with nasal polyps compare to patients with 24 AIA with-
out polyps [36].
Despite the evidence supporting a role for leukotrienes
other authors have failed to demonstrate a role for cysLTs
in CRS. A study by Kountakis et al [37] showed that mean
cysLTs levels were similar in CRS patients with eosi-
nophilic versus non eosinophilic and in patients with pol-
yps versus without polyp. Also cysLTs levels did not
correlate with severity of CRS according to CT findings,
endoscopy findings, or symptom scores.
Conclusion
While these initial results do not support that polymor-
phisms in genes assessed involved in the leukotriene path-
ways are contributing to the pathogenesis of CRS, this
initial study was not powered to detect polymorphisms
with relative risk of 2.0 or less, where we could expect
many gene effects for complex diseases to occur. Thus,
despite this lack of significant association noted in this
study, we believe that validation with external popula-
tions and the use of better-powered studies in the future
may allow more conclusive findings.
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